Skip to main content
. 2020 Apr 24;37(6):2988–2998. doi: 10.1007/s12325-020-01300-6

Table 2.

Dosing, consumption and bleeding rates with rIX-FP prophylaxis and prior FIX product prophylaxis in patients with haemophilia B in Italy, Belgium and the UK

Italy Belgium UK
rIX-FP (n = 44) Prior FIX (n = 44) rIX-FP (n = 7) Prior FIX (n = 7) rIX-FP (n = 22) Prior FIX (n = 22)
Dose, IU/kg/week 38.6 ± 16.5 84.4 ± 34.4 30.3 ± 11.5 103.1 ± 60.9 29.2 ± 8.5 71.7 ± 18.9
ABR 0.2 ± 0.4 3.5 ± 5.7 0.4 ± 0.8 6.6 ± 3.4 1.0 ± 0.9 3.1 ± 1.4
AsBR 0.02 ± 0.2 0.7 ± 1.0 0.0 ± 0.0 3.0 ± 3.3 0.4 ± 0.6 2.0 ± 1.5
Patients with zero bleeds, % 84.1 13.6 71.4 14.3 36.4 0.0
Patients with zero spontaneous bleeds, % 97.7 50.0 100.0 42.9 63.6 22.7

Data are presented as mean ± SD unless otherwise stated

ABR, annualised bleeding rate; AsBR, annualised spontaneous bleeding rate; SD, standard deviation